Live attenuated vaccines have proven to be the most efficient human vaccines for many serious infectious diseases. When compared to their dead counterparts, live vaccines induce superior immune protection and lasting memory. But despite the efficacy of live vaccines, concerns over their safety have led to vaccine refusal by some and withholding their administration to the very young, the elderly and immunocompromised. Preservation and delivery of live vaccines especially to impoverished areas in developing countries is difficult and expensive. Understanding the molecular basis for the efficacy of live vaccines is significant because it would enable targeting of the relevant immune pathways that induce optimal and long-lasting protective immunity. Importantly, it would set the stage for the development of vaccines that are safe and afford the same protection as live vaccines, alleviating public fears and increasing the segment of the population that is vaccinated. We began our work eight years ago with the hypothesis that innate immune cells sense microbial viability as a distinct set of pathogen associated molecular patterns (PAMPs), and we identified bacterial messenger RNA (mRNA) as a vita-PAMP that signifies bacterial viability and mobilizes a tailored immune response not warranted for dead microorganisms. The Toll-like receptor (TLR) signaling adaptor TRIF plays a central role here upstream of inflammatory type I interferon and NLRP3 inflammasome pathways. Adding bacterial mRNA to dead bacteria recapitulates these innate responses, and supplementing a dead vaccine with bacterial mRNA (what we call a vita-vaccine) augments its performance in mice. A vita-vaccine performed similarly to a live vaccine in uniquely eliciting a follicular T helper cell response (that helps B cells), germinal center formation, and B cell isotype class switching, all in a TRIF-dependent manner. These studies provide strong evidence that vita-vaccine versions of existing vaccines could represent a significant advance in being able to combine the efficacy of live vaccines with the safety of dead vaccines. The three overlapping areas we will investigate in this project are: 1. We will determine how adaptive immunity elicited by the supplementation of a dead bacterial vaccine with the vita-PAMP bacterial mRNA compares to that elicited by PAMPs such as bacterial lipopeptides and others. 2. We will investigate how bacterial mRNA impacts the performance of subunit vaccines. We will test vita- vaccine versions of the licensed anthrax subunit vaccine and Influenza A virus monovalent subunit vaccine. 3. We will test a vita-vaccine version of a trivalent inactivated Influenza virus vaccine and compare it to the live attenuated influenza vaccine. The completion of these studies should provide sufficient experimental evidence to warrant the use of bacterial mRNAs as superior vita-adjuvants that restore the signatures of microbial viability to dead vaccines and improve existing inactivated and subunit vaccines for protection against either bacterial or viral diseases.

Public Health Relevance

PROPOSAL NARRATIVE Vaccines comprised of live attenuated microorganisms are superior to their dead counterparts, yet concerns about the safety of live vaccines have dampened their popularity. We discovered that bacterial messenger RNA signals microbial viability to the immune system and when used as an adjuvant augments the performance of dead vaccines. Armed with bacterial RNA as a new adjuvant, the work we propose here will advance the development of dead vaccines that work as well as live ones, improve the performance of existing vaccines, and salvage vaccines that may have been shelved due to inefficacy, all while achieving superior protection and maintaining desired safety.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI127658-03
Application #
9357501
Study Section
Vaccines Against Microbial Diseases Study Section (VMD)
Program Officer
Lapham, Cheryl K
Project Start
2016-09-23
Project End
2021-08-31
Budget Start
2017-09-01
Budget End
2018-08-31
Support Year
3
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065
García-Sastre, Adolfo (2017) Ten Strategies of Interferon Evasion by Viruses. Cell Host Microbe 22:176-184
Martín-Vicente, María; Medrano, Luz M; Resino, Salvador et al. (2017) TRIM25 in the Regulation of the Antiviral Innate Immunity. Front Immunol 8:1187
Moretti, Julien; Roy, Soumit; Bozec, Dominique et al. (2017) STING Senses Microbial Viability to Orchestrate Stress-Mediated Autophagy of the Endoplasmic Reticulum. Cell 171:809-823.e13
Blander, J Magarian (2017) The many ways tissue phagocytes respond to dying cells. Immunol Rev 277:158-173
Moretti, Julien; Blander, J Magarian (2017) Cell-autonomous stress responses in innate immunity. J Leukoc Biol 101:77-86
Schotsaert, Michael; García-Sastre, Adolfo (2017) Inactivated influenza virus vaccines: the future of TIV and QIV. Curr Opin Virol 23:102-106
Moretti, Julien; Blander, J Magarian (2014) Insights into phagocytosis-coupled activation of pattern recognition receptors and inflammasomes. Curr Opin Immunol 26:100-10
Blander, J Magarian (2014) A long-awaited merger of the pathways mediating host defence and programmed cell death. Nat Rev Immunol 14:601-18
Blander, J Magarian; Sander, Leif E (2012) Beyond pattern recognition: five immune checkpoints for scaling the microbial threat. Nat Rev Immunol 12:215-25
Agudo, Judith; Ruzo, Albert; Kitur, Kipyegon et al. (2012) A TLR and non-TLR mediated innate response to lentiviruses restricts hepatocyte entry and can be ameliorated by pharmacological blockade. Mol Ther 20:2257-67

Showing the most recent 10 out of 11 publications